Bill Gates backs Schrödinger's $85M ven­ture raise for its stand­out com­pu­ta­tion­al drug dis­cov­ery plat­form

Com­pu­ta­tion­al chem­istry in drug dis­cov­ery is noth­ing new — the idea that more pre­cise mol­e­c­u­lar de­sign can speed up and op­ti­mize R&D is al­ways ap­peal­ing to an in­dus­try des­per­ate for a high­er re­turn of in­vest­ment — but it might just be gain­ing steam again. Just look at the list of in­vestors in Schrödinger’s lat­est round.

Deer­field Man­age­ment, Baron, Qim­ing Ven­ture Part­ners, and GV (for­mer­ly Google Ven­tures) all chipped in­to the $85 mil­lion Se­ries E, co-led by two of Schrödinger’s big be­liev­ers: Bill Gates, who’s sup­port­ed pre­vi­ous rounds; and WuXi AppTec, which launched a drug dis­cov­ery joint ven­ture with the com­pa­ny just weeks ago.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER